Patents Assigned to Exicure, Inc.
  • Patent number: 10208310
    Abstract: TNF? antisense oligonucleotides are provided herein. Methods of treating TNF? diseases or disorders using the TNF? antisense oligonucleotides and related products are provided.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: February 19, 2019
    Assignee: Exicure, Inc.
    Inventors: Christopher C. Mader, Tiffany L. Halo, Sergei Gryaznov, Richard Kang, Weston Daniel
  • Patent number: 10182988
    Abstract: Liposomes termed as small unilamellar vesicles (SUVs), can be synthesized in the 20-50 nm size range, but encounter challenges such as instability and aggregation leading to inter-particle fusion. This limits their use as a therapeutic delivery agent. Increasing the surface negative charge of SUVs, via the attachment of anionic entities such as DNA/RNA, increases the colloidal stability of these vesicles. Additionally, the dense spherical arrangement and radial orientation of nucleic acids exhibits unique chemical and biological properties, unlike their linear counterparts. These liposomal particles, are non-toxic and though anionic, can efficiently enter cells without the aid of ancillary cationic transfection agents in a non-immunogenic fashion. These exceptional properties allow their use as delivery agents for gene regulation in different therapies and offer an alternative platform to metal core spherical nucleic acids.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: January 22, 2019
    Assignees: NORTHWESTERN UNIVERSITY, EXICURE, INC.
    Inventors: Chad A. Mirkin, Sonbinh T. Nguyen, Resham Singh Banga, Natalia Chernyak, Sergei Gryaznov, Aleksandar Radovic-Moreno, Christopher Mader
  • Publication number: 20180327741
    Abstract: Optimized inhibitory nucleic acids are provided. The nucleic acids have sequences which include an optimal inhibitory motif, such as a GGG. Related methods are also described.
    Type: Application
    Filed: January 14, 2016
    Publication date: November 15, 2018
    Applicant: Exicure, Inc.
    Inventors: Weston DANIEL, Scott MIX
  • Publication number: 20180320184
    Abstract: Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof.
    Type: Application
    Filed: May 15, 2018
    Publication date: November 8, 2018
    Applicant: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Christopher C. Mader, Subbarao Nallagatla, Warefta Hasan, Aaron Love, Sergei Gryaznov
  • Publication number: 20180214376
    Abstract: The invention relates to spherical nucleic acids for the delivery of lipid nucleic acid particles. The lipid nucleic acid particles containing one or more therapeutic agents are coated with an oligonucleotide shell to enhance delivery.
    Type: Application
    Filed: July 14, 2016
    Publication date: August 2, 2018
    Applicant: Exicure, Inc.
    Inventor: David A. GILJOHANN
  • Publication number: 20180042848
    Abstract: Immunoregulatory spherical nucleic acids (irSNAs) composed of a lipid containing core and an inert Nucleic non-TLR antagonistic oligonucleotide shell are provided. Acid Shell These it-SNAs are useful for modulating an immune response.
    Type: Application
    Filed: February 18, 2016
    Publication date: February 15, 2018
    Applicant: Exicure, Inc.
    Inventors: Sergei Gryaznov, Aleksandar Filip Radovic-Moreno, Christopher C. Mader, Tiffany L. Halo, Richard Kang, Subbarao Nallagatla, Clayton Rische, Sagar Anantatatmula
  • Publication number: 20170175121
    Abstract: Stable self-assembling nucleic acid nanostructures comprising: —a plurality of oligonucleotides, —a plurality of G-quadruplex forming nucleic acids linked to the plurality of oligonucleotides, and —a plurality of G-quadruplex stabilizing domains linked to the G-quadruplex forming nucleic acids. The nucleic acid nanostructures are suitable for use as agonists or antagonists of nucleic acid interacting complexes, such as Toll-like receptors; for inhibiting DNA or RNA expression; for stimulating or inhibiting an immune response; and for treating diseases such as cancer, infectious diseases, allergies and allergic diseases, and autoimmune diseases.
    Type: Application
    Filed: April 3, 2015
    Publication date: June 22, 2017
    Applicant: Exicure, Inc.
    Inventor: Sergei Gryaznov
  • Publication number: 20170157048
    Abstract: Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.
    Type: Application
    Filed: June 4, 2015
    Publication date: June 8, 2017
    Applicant: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Richard Kang, Subbarao Nallagatla, Christopher C. Mader, Sergei Gryaznov
  • Publication number: 20160194642
    Abstract: Aspects of the invention relate to nanoscale constructs and related methods and compositions thereof. The compositions of the invention are useful for treating disorders that are sensitive to levels of immune cell activation, such as autoimmune disease or other inflammation based disease or disorder.
    Type: Application
    Filed: July 25, 2014
    Publication date: July 7, 2016
    Applicant: Exicure, Inc
    Inventors: Sergei Gryaznov, Christopher C. Mader, Tiffany L. Halo, Aleksandar Filip Radovic-Moreno, Clayton Rische, Sagar Anantatmula
  • Publication number: 20160186178
    Abstract: Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof.
    Type: Application
    Filed: July 25, 2014
    Publication date: June 30, 2016
    Applicant: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Christopher C. Mader, Subbarao Nallagatla, Warefta Hasan, Aaron Love, Sergei Gryaznov